DAFNA Capital Management LLC Boosts Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• DAFNA Capital Management LLC increased its stake in Structure Therapeutics by 66.2%, acquiring an additional 23,500 shares, bringing its total ownership to approximately 59,000 shares valued at about $1,021,000.
• Several institutional investors have also ramped up their holdings in Structure Therapeutics, with Wells Fargo & Company MN raising its stake by 202.5% in the previous quarter.
• The stock has received multiple "buy" ratings from analysts, with a consensus price target of $75.71, despite missing earnings estimates in the latest quarter.

DAFNA Capital Management LLC increased its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 66.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,000 shares of the company's stock after acquiring an additional 23,500 shares during the period. DAFNA Capital Management LLC owned about 0.10% of Structure Therapeutics worth $1,021,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Deep Track Capital LP grew its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after acquiring an additional 1,579,492 shares during the period. Vestal Point Capital LP boosted its stake in Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in Structure Therapeutics during the 4th quarter valued at $13,560,000. Ameriprise Financial Inc. boosted its stake in Structure Therapeutics by 29.4% during the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after purchasing an additional 322,601 shares during the last quarter. Finally, Baker BROS. Advisors LP boosted its stake in Structure Therapeutics by 322.9% during the 4th quarter. Baker BROS. Advisors LP now owns 361,565 shares of the company's stock valued at $9,806,000 after purchasing an additional 276,065 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock traded down $0.37 during trading on Wednesday, reaching $19.71. 6,056,550 shares of the stock traded hands, compared to its average volume of 890,408. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -18.77 and a beta of -1.88. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $13.22 and a 52-week high of $45.37. The business has a fifty day simple moving average of $18.91 and a two-hundred day simple moving average of $20.77.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. HC Wainwright lowered their price target on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Guggenheim decreased their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, JMP Securities decreased their target price on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of "Buy" and an average target price of $75.71.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.